ZEROKEY
ZeroKey today unveiled their second-generation technology, Quantum RTLS™, the world’s most accurate large-scale 3D real-time location system (RTLS). The technology enables unprecedented operational visibility of manufacturing , supply chain, logistics , and human-centric workflows to drive real-time optimization and integration of processes across entire organizations. Quantum RTLS ™ provides hyper-accurate digitization of the location of assets for closed-loop control of highly dynamic workflows, real-time monitoring of human-centric processes, process analytics, and high-fidelity digital twinning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005976/en/
To perform data-driven decision-making, businesses must be able to derive actionable information from the data they are collecting, and that is where ZeroKey’s technology excels. The true value of a connected asset is unlocked through Quantum RTLS™ location technology, enabling an organization to make better-informed and more timely decisions. Through the digitization of both time and location, ZeroKey provides the highest level of accuracy and actionable analytics through its Spatial Intelligence Platform , giving customers 4D operational intelligence that truly delivers on the promise of Industry 4.0.
“The hyper accuracy of Quantum RTLS empowers companies to solve problems that have never been solved before in industrial environments,” says Matthew Lowe, CEO & Co-founder at ZeroKey. “Production efficiency and operational visibility are exponentially increased when operations are digitized in 4D with millimeter accuracy. Our technology enables unprecedented process optimization and quality control, allowing businesses to maximize their output while reducing costly errors.”
Features and benefits of Quantum RTLS™ include:
- Millimeter-level accuracy
- Real-time 3D tracking
- Operational visibility from a globally accessible platform
- Unprecedented analytics and digitization of physical processes
- Wide-area multi-floor/multi-room/multi-building scalability
- Rapid deployments with patented self-calibration technology
- Easy integration of third-party platforms through open API
Quantum RTLS™ will be available on June 30, 2022. For more information, visit https://www.zerokey.com/products/quantum-rtls .
About ZeroKey: ZeroKey’s patented technology, Quantum RTLS™, is the world’s only wide-area, 3D, millimeter-level RTLS technology that closes the IIoT utility gap in factories, warehouses, and industrial environments worldwide, including with six of the largest ten major automotive OEMs. Powered by ultrasonics, Quantum RTLS™ delivers high performance and reliability at any scale with unparalleled simplicity and flexibility. With a range of trackable tags suitable for diverse applications, ZeroKey technology tracks the assets, processes, goods, and personnel critical to modern business with unprecedented resolution. For more information, visit www.zerokey.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005976/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom